SCHEMBL1301839

SCHEMBL1301839

C=CC/C=C/COC(C)=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 2/20 0.38
USP2 O75604 2/20 0.38
MAPT P10636 2/20 0.38
RECQL P46063 1/20 0.38
ALDH1A1 P00352 8/20 0.37
ALOX15 P16050 2/20 0.37
HSD17B10 Q99714 1/20 0.37
HPGD P15428 1/20 0.33
TSHR P16473 2/20 0.32
PGR P06401 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
HTR1A P08908 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRM3 P20309 1/20 0.31
TBXA2R P21731 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1301840 1.00 CYP3A4 (0.38) CYP3A4SMN1; SMN2LMNAUSP2MAPT
SCHEMBL8015606 0.88 CYP3A4 (0.36) CYP3A4SMN1; SMN2LMNAUSP2MAPT
SCHEMBL221749 0.83 ALDH1A1 (0.50) CYP3A4SMN1; SMN2LMNAUSP2MAPT
SCHEMBL74779 0.83 ALDH1A1 (0.50) CYP3A4SMN1; SMN2LMNAUSP2MAPT
SCHEMBL271027 0.83 ALDH1A1 (0.50) CYP3A4SMN1; SMN2LMNAUSP2MAPT
SCHEMBL16124303 0.80 ALDH1A1 (0.39) SMN1; SMN2LMNAALDH1A1ALOX15HSD17B10
SCHEMBL22022746 0.80 CYP3A4 (0.35) CYP3A4SMN1; SMN2ALDH1A1HSD17B10TSHR
SCHEMBL31217853 0.79 TSHR (0.47) CYP3A4SMN1; SMN2LMNAUSP2MAPT
SCHEMBL64376 0.79
SCHEMBL15237136 0.78 ALDH1A1 (0.41) CYP3A4SMN1; SMN2LMNAUSP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025096734-A1 MICROCAPSULES FMC CORPORATION (US) 2025-05-08 WO disclosed
EP-3586961-B1 METHOD FOR MANUFACTURING CATALYST LIQUID KURARAY CO (JP) 2023-06-07 EP disclosed
US-11628430-B2 Method for manufacturing catalyst liquid KURARAY CO., LTD. (JP) 2023-04-18 US disclosed
CN-110290872-B Method for producing catalyst liquid 株式会社可乐丽 2022-10-18 CN disclosed
US-8367618-B2 Cyclosporin analogues for preventing or treating hepatitis C infection ENANTA PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-20110266361-A1 PHEROMONE DISPENSER BASF SE (DE) 2011-11-03 US disclosed
US-20100196316-A1 CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION ENANTA PHARMACEUTICALS, INC. 2010-08-05 US disclosed
US-7041619-B2 Phosphonium salts and processes for production of and uses for the same, and phosphines deriving the same and processes for production of the phosphines KURARAY CO., LTD. (JP) 2006-05-09 US disclosed
EP-1249455-B1 Phosphorus-containing molecules and processes for production of and uses for the same, and phosphines deriving the same and processes for production of the phosphines KURARAY CO (JP) 2005-02-16 EP disclosed
US-20040260118-A1 Phosphonium salts and processes for production of and uses for the same, and phosphines deriving the same and processes for production of the phosphines KURARAY CO. LTD. (JP) 2004-12-23 US disclosed
US-6790985-B2 USEFUL AS COMPONENTS OF CATALYSTS ACCELERATING TELOMERIZATION OF A CONJUGATED DIENE AND AN ACTIVE HYDROGEN COMPOUND KURARAY CO., LTD. (JP) 2004-09-14 US disclosed
US-20020183196-A1 Phosphonium salts and processes for production of and uses for the same, and phosphines deriving the same and processes for production of the phosphines KURARAY CO. LTD, (JP) 2002-12-05 US disclosed
EP-1249455-A1 Phosphonium salts and processes for production of and uses for the same, and phosphines deriving the same and processes for production of the phosphines Kuraray Co., Ltd. (JP) 2002-10-16 EP disclosed
EP-0704417-B1 Process for producing octadienes KURARAY CO (JP) 1999-01-20 EP disclosed
US-5763718-A Process for producing octadienes KURARAY CO., LTD. (JP) 1998-06-09 US disclosed
EP-0704417-A2 Process for producing octadienes KURARAY CO., LTD. (JP) 1996-04-03 EP disclosed
EP-0296550-B1 Phosphonium salts and processes for production of and uses for the same KURARAY CO (JP) 1993-12-29 EP disclosed
US-5100854-A Telomerization catalysts KURARAY CO., LTD. (JP) 1992-03-31 US disclosed
US-4992609-A Telomerization catalysts KURARAY CO., LTD. (JP) 1991-02-12 US disclosed
US-4927960-A TELOMERIZATION CATALYST KURARAY COMPANY, LTD. (JP) 1990-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11628430-B2 Method for manufacturing catalyst liquid OSGEP, PNP, ALK CYP3A4 297/4885SMN1; SMN2 1434/4885LMNA 1081/4885
US-20100196316-A1 CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION HAVCR2, CHP1, PTPRC CYP3A4 434/4885SMN1; SMN2 4279/4885LMNA 3948/4885
US-20040260118-A1 Phosphonium salts and processes for production of and uses for the same, and phosphines deriving the same and processes for production of the phosphines PHOSPHO1, INPP5B, PIP5K1A CYP3A4 2126/4885SMN1; SMN2 3584/4885LMNA 4590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.